Long Noncoding RNA LIFR-AS1: A New Player in Human Cancers | Zendy

Zhiqun Bai | Zendy; Xuemei Wang | Zendy; Zhen Zhang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Long Noncoding RNA LIFR-AS1: A New Player in Human Cancers

Author(s) -

Zhiqun Bai,

Xuemei Wang,

Zhen Zhang

Publication year - 2022

Publication title -

biomed research international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.772

H-Index - 126

eISSN - 2314-6141

pISSN - 2314-6133

DOI - 10.1155/2022/1590815

Subject(s) - leukemia inhibitory factor receptor , long non coding rna , carcinogenesis , biology , cancer research , gene , rna , leukemia inhibitory factor , genetics , embryonic stem cell

Emerging evidence has indicated that aberrantly expressed long noncoding RNAs (lncRNAs) play a vital role in various biological processes associated with tumorigenesis. Leukemia inhibitory factor receptor antisense RNA1 (LIFR-AS1) is a recently identified lncRNA transcribed in an antisense manner from the LIFR gene located on human chromosome 5p13.1. LIFR-AS1 regulates tumor proliferation, migration, invasion, apoptosis, and drug resistance through different mechanisms. Its expression level is related to the clinicopathological characteristics of tumors and plays a key role in tumor occurrence and development. In this review, we summarize the role of LIFR-AS1 in the development and progression of different cancers and highlight the potential for LIFR-AS1 to serve as a biomarker and therapeutic target for a variety of human cancers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research